Prostate cancer: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• PSMA 273
• AR 16
• TP53 2
• PARP 13
• PTEN 4
• AKT 1
• BRCA2 7
• BRCA1 9
• PI3K 2
• STAT3 0
• PD-L1 6
• mTOR 1
• PD-1 13
• EZH2 7
• MYC 1
• B7-H3 8
• EGFR 2
• CTNNB1 1
• JNK 0
• ERK 0
• HIF-1 0
• VEGF 2
• BCL-2 0
• AMPK 0
• CDK4/6 4
• HER2 6
• MAPK 0
• NRF2 0
• FAK 0
• YAP 0
• PPAR 0
• IL-6 0
• STING 0
• COX-2 0
• CTLA-4 0
• DLL3 6
• GLP-1 1
• GPX4 0
• HSP90 0
• ATM 1
• HDAC 0
• IL-15 4
• METTL3 1
• BRD4 0
• HER3 2
• JAK 1
• CXCR4 0
• TROP2 3
• CD47 1
• IGF1R 0
• IL-1 0
• MET 1
• PALB2 4
• RB1 0
• TNF 0
• APOE 0
• FGFR 1
• KRAS 0
• MDM2 0
• MEK 0

6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Targeting stress signaling pathways to enhance prostate cancer immunotherapy (IMMSTRESS)

  Deutsches Krebsforschungszentrum Heidelberg· Heidelberg, Germany· EU contribution €202,125· until Aug 2029

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF

  Circulating Tumor Cell-informed RADioresponse Assessment from heme-axis signatuRes (CTC-RADAR)

  Koc University· Istanbul, Türkiye· EU contribution €398,612· until Dec 2029· 2 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  EXPLORING THE MECHANISM OF METASTASIS/DEVELOPMENT OF NEW TESTS TO ENROLL CIRCULATING TUMOR CELLS (CTCs) INTO CLINICAL PRACTICE (CTC4CLINIC)

  Panepistimio Patron· Rio Patras, Greece· EU contribution €796,590· until Dec 2030· 7 countries

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  Exploitation of bioorthogonal click-to-release chemistry for precision cancer therapy (click-to-cure)

  Kobenhavns Universitet· Kobenhavn, Denmark· EU contribution €247,553· until Dec 2028· 2 countries

  The disease is named only in the funder's project summary, not in the title.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF

  A Proteoform-Resolved Lateral Flow Immunoassay with Antibody Mimics and Engineered Release for Precise Prostate Cancer Diagnosis (PRIME)

  The Chancellor, Masters and Scholars of the University of Oxford· Oxford, United Kingdom· EU contribution €260,348· until Sept 2028

5 of 32 running projects, newest first. Listed amounts together: €116.1m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 42
• Organoids 15
• Mendelian Randomization Analysis 38
• CRISPR-Cas Systems 14
• Gene Expression Profiling 153
• Sequence Analysis, RNA 11
• Whole Genome Sequencing 9
• Exome Sequencing 4
• Proteomics 47
• Metabolomics 27
• Mass Spectrometry 16
• Flow Cytometry 58
• Immunohistochemistry 120
• Liquid Biopsy 30
• Circulating Tumor DNA 32
• Xenograft Model Antitumor Assays 287
• Positron-Emission Tomography 125
• Magnetic Resonance Imaging 464
• Machine Learning 122
• Deep Learning 101
• Cohort Studies 276
• Genome-Wide Association Study 61

• Integration of bulk RNA-seq data with single-cell RNA-seq data to identify urinary biomarkers derived from prostate tumor tissues.

  BMC Urol, Aug 2026

• Integrated miRNA Sequencing and Network Analysis Reveal a Molecular Continuum Between Peritumoral and Tumor Tissue in Prostate Cancer.

  Int J Mol Sci, Jul 2026

• RNAlater-compatible protocol for nuclei isolation from radical prostatectomy prostate cancer resections, enabling single-nucleus resolution RNA-seq.

  Sci Rep, Jun 2026

• Single-cell and spatial RNA sequencing in prostate cancer.

  Nat Rev Urol, May 2026

• CEP-IP: An explainable framework for cell subpopulation identification in single-cell transcriptomics.

  Comput Methods Programs Biomed, Apr 2026

• Advances in the identification of novel cell signatures in benign prostatic hyperplasia and prostate cancer using single-cell RNA sequencing.

  Front Immunol, Jan 2026

• Unlocking single-cell level and continuous whole-slide insights in spatial transcriptomics with PanoSpace.

  Nat Comput Sci, Jan 2026

• Exploring the key functions of T cells and the regulation of the immune microenvironment in prostate cancer using single-cell RNA sequencing and bulk RNA sequencing.

  Autoimmunity, Dec 2025

• Exploring tumor dynamics and responses of prostate cancer to IL-27 based treatment combinations through biodynamic imaging and RNA sequencing analyses.

  Sci Rep, Nov 2025

• Integrated Analysis of Single-Cell RNA Sequencing and Machine Learning Reveals a T Cell-Specific PANoptosis Signature Predicting Prognosis and Immunotherapy in Prostate Cancer.

  Hum Mutat, Nov 2025

See which targets of this disease your abstract mentions, and go to the people working on them.